Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

Could BPC 157 Help With ED? Our Team’s Analysis

Let's talk about a topic that's often shrouded in silence but affects millions: erectile dysfunction. It's a deeply personal and frustrating issue, but our team has found that framing it correctly is the first step. This isn't just a performance problem; more

Let's talk about a topic that's often shrouded in silence but affects millions: erectile dysfunction. It's a deeply personal and frustrating issue, but our team has found that framing it correctly is the first step. This isn't just a performance problem; more often than not, it's a signal from the body that something deeper—often related to vascular or neurological health—is amiss. It’s a check engine light for your systemic well-being. And in the world of advanced peptide research, where we're constantly looking at compounds that promote systemic repair, a fascinating molecule keeps entering the conversation: BPC-157.

We've seen the chatter in forums and the questions in research circles. The inquiry, "can BPC 157 help with erectile dysfunction?" is becoming more common, and for good reason. BPC-157 is renowned for its extraordinary healing capabilities, from mending torn tendons to soothing gut inflammation. So, it's only natural to wonder if those restorative powers could extend to the intricate systems responsible for sexual function. Our goal here isn't to give you a simple yes or no. The science is far too nuanced for that. Instead, we're going to pull back the curtain on the mechanisms, explore the plausible connections, and give you an expert, unflinching look at what the research suggests. This is about connecting the dots between a powerful healing peptide and a complex physiological challenge.

What Exactly Is BPC-157? A Refresher

Before we dive into the deep end, let's get everyone on the same page. What is this compound we're talking about? BPC-157, which stands for Body Protection Compound 157, is a synthetic peptide chain made of 15 amino acids. Its sequence is derived from a protective protein found naturally in human gastric juice. Think about that for a second. Its origin is in one of the most resilient and regenerative environments in the human body—the stomach.

For years, researchers have been captivated by its pleiotropic effects, meaning it produces multiple, often unrelated, beneficial actions throughout the body. It’s not a sniper rifle targeting one specific issue; it’s more like a multi-tool for cellular repair. Its primary claim to fame in the research community is its profound ability to accelerate healing. We're talking about studies showing enhanced recovery in everything from muscle sprains and ligament tears to skin burns and even bone defects. It accomplishes this through a cascade of biological processes, most notably by promoting angiogenesis—the formation of new blood vessels—and modulating growth factors.

But its influence doesn't stop at structural repair. BPC-157 is also a potent anti-inflammatory agent and a cytoprotective compound, meaning it protects cells from harm. This is why it's a cornerstone in gut health research, showing potential in studies related to inflammatory bowel disease (IBD), leaky gut syndrome, and ulcers. It helps maintain the integrity of the gut lining, which is a critical, non-negotiable element of overall health. At Real Peptides, ensuring the absolute purity and precise amino-acid sequencing of compounds like our BPC 157 Peptide is paramount, because researchers studying these complex mechanisms need a stable, reliable foundation for their work. Without that guarantee, the data is meaningless.

So, you have a peptide known for building new blood vessels, protecting cells, reducing inflammation, and accelerating tissue repair. Now, let’s look at what causes erectile dysfunction.

Understanding the Root Causes of Erectile Dysfunction

Erectile dysfunction is almost never a standalone problem. It's a symptom. And to understand how something might help, we first have to understand the underlying machine and where it's breaking down. Honestly, the mechanics of an erection are a biological marvel, requiring a perfect symphony between the brain, nerves, hormones, and, most critically, the cardiovascular system.

When that symphony is out of tune, it's usually due to one of these core issues:

Vascular Problems: This is the big one. By far the most common cause of ED, especially as men age. Healthy erections are all about blood flow. The penile tissue, the corpus cavernosum, needs to relax and allow blood to rush in and become trapped. Conditions like atherosclerosis (hardening of the arteries), high blood pressure, and high cholesterol all damage the delicate lining of the blood vessels (the endothelium), impairing their ability to dilate. If the plumbing is clogged or damaged anywhere in the body, it’s going to be compromised in this highly specialized area, too.

Neurological Factors: The initial signal for an erection starts in the brain and travels down the spinal cord to the nerves in the pelvis. Any disruption along this pathway can cause problems. We see this frequently in cases of diabetes (which can cause diabetic neuropathy), multiple sclerosis, spinal cord injuries, or nerve damage resulting from prostate surgery. If the command signal can't get through, the physical response can't happen.

Hormonal Imbalances: While less common, hormones play a key role. Low testosterone can certainly reduce libido (the desire for sex), which can contribute to ED. But other hormonal issues, like thyroid problems or high prolactin levels, can also throw the system out of balance.

Systemic Inflammation & Oxidative Stress: This is a more modern understanding, but it's crucial. Chronic, low-grade inflammation wreaks havoc on the entire body, and the vascular system is particularly vulnerable. It damages the endothelium, reduces the production of nitric oxide (a vital molecule for blood vessel relaxation), and contributes to the progression of vascular disease. It's a silent threat that directly undermines erectile function.

The common thread here? Damage. Damage to blood vessels, damage to nerves, and damage from inflammation. It's a problem of systemic breakdown and compromised biological hardware.

The Core Question: Can BPC-157 Help with Erectile Dysfunction?

Now we get to the heart of it. Given what we know about BPC-157's restorative talents and the root causes of ED, is there a connection? We can't stress this enough: there are currently no large-scale, double-blind, placebo-controlled human trials that have been published specifically investigating BPC-157 as a direct treatment for erectile dysfunction. Anyone who claims otherwise is misrepresenting the current state of the science.

So, does that mean it's a dead end?

Absolutely not. The connection isn't based on direct evidence for this specific condition, but on compelling, mechanistic inference. It’s about looking at BPC-157's well-documented effects and overlaying them onto the known pathologies of ED. The hypothesis is that BPC-157 doesn't treat ED directly; instead, it may work to repair the underlying systemic damage that causes ED. It’s a foundational approach, not a symptomatic one. This is a critical distinction that changes the entire conversation.

Exploring the Potential Mechanisms of Action

This is where it gets really interesting. If BPC-157 were to have a positive impact on erectile function, it would likely be through several of its signature biological pathways working in concert. Let's break down the most plausible ones.

1. Angiogenesis and Vascular RepairThis is arguably the most compelling mechanism. As we mentioned, erections are entirely dependent on robust blood flow. BPC-157 is a potent angiogenic agent, meaning it stimulates the creation of new blood vessels. In numerous animal studies, it has been shown to significantly increase blood vessel density in damaged tissues, effectively creating new pathways for blood to flow. Our experience shows this is its most celebrated function in research.

Imagine the vascular network of the penis as a system of small roads and highways. In many men with ED, these roads are old, cracked, and full of potholes (plaque and endothelial damage). Traditional ED medications act like temporary traffic controllers, forcing more cars down these damaged roads for a short period. BPC-157, theoretically, works like a construction crew. It doesn't just manage traffic; it repairs the old roads and builds entirely new ones. By improving the fundamental integrity and density of the vascular network, it could restore the system's ability to handle the massive influx of blood required for a firm erection. It’s a long-term infrastructure project, not a short-term fix.

2. Modulation of the Nitric Oxide (NO) SystemNitric oxide is the master key to erections. It's a signaling molecule that tells the smooth muscle cells in the arteries of the penis to relax, allowing for vasodilation—the widening of blood vessels. Without sufficient NO, this relaxation can't happen effectively. Many things, from aging to poor diet to vascular disease, can impair the body's ability to produce and utilize NO.

Here’s the link: some research suggests that BPC-157 can interact with and modulate the nitric oxide system. One study found that BPC-157 could counteract the effects of an L-arginine analogue that blocks NO synthesis. While the exact mechanism is still being unraveled, the idea is that BPC-157 might help protect the NO system from dysfunction or even restore its proper function. By ensuring the NO signaling pathway is working optimally, it could directly support the primary chemical process required for an erection. It's a delicate and powerful interaction.

3. Neurogenesis and Nerve ProtectionFor men whose ED stems from nerve damage, this pathway is incredibly relevant. Whether it's from a pelvic injury, prostate surgery, or the slow creep of diabetic neuropathy, damaged nerves can't transmit the brain's signals effectively. BPC-157 has demonstrated significant neuroprotective properties in various studies. It's been shown to promote the regeneration of peripheral nerves and protect neurons from various toxins and injuries.

If BPC-157 can encourage the repair and regrowth of the crucial pelvic nerves that control erectile function, it could potentially restore a connection that was previously lost or weakened. This would be a game-changer, as nerve damage is one of the most difficult-to-treat causes of ED. The research here is still in early stages, but the potential is formidable.

4. Systemic Anti-Inflammatory EffectsAs we established, chronic inflammation is a villain in the story of vascular health. It stiffens arteries and damages the endothelium. BPC-157 is a known anti-inflammatory, but it doesn't work like a typical NSAID. Instead of just blocking an enzyme, it seems to modulate the inflammatory response at a more fundamental level, helping to rebalance the system. By lowering the systemic inflammatory burden, BPC-157 could improve the health of every blood vessel in the body, including those essential for sexual function. This is a broader, more holistic benefit, but no less important.

A Comparison of Approaches to Erectile Function

To put BPC-157's potential role in context, it's helpful to see how it stacks up against other approaches. Our team put together a simple comparison to highlight the different philosophies of treatment. This isn't about which is 'best,' but about understanding the different tools and their intended jobs.

Primary Mechanism

Blocks PDE5 enzyme to enhance the effect of nitric oxide, causing vasodilation.

Acts on melanocortin receptors in the central nervous system to increase sexual arousal (libido).

Promotes systemic healing: angiogenesis, nerve repair, anti-inflammation, NO system modulation.

Target

Symptomatic (works on-demand for a single event).

Neurological/Psychological (targets desire and arousal pathways in the brain).

Foundational/Systemic (aims to repair underlying physiological damage).

Onset of Action

Fast (typically 30-60 minutes).

Relatively fast (can take a few hours).

Slow and cumulative (effects would build over weeks or months of consistent protocol).

Primary Use Case

Addressing immediate performance for sexual activity.

Addressing low libido or psychogenic ED.

Research into repairing underlying vascular, nerve, or inflammatory damage causing the dysfunction.

As you can see, these compounds aren't really competing. They're playing entirely different games. PDE5 inhibitors are a fantastic tool for managing a symptom. PT-141 is a unique agent for targeting arousal. BPC-157, on the other hand, represents a completely different paradigm: the possibility of healing the system itself. This is what makes the research so compelling.

What the Research Doesn't Tell Us (Yet)

Let's be honest, though. We have to balance the exciting potential with a healthy dose of scientific reality. The leap from preclinical animal studies on tissue repair to confirmed efficacy for human erectile dysfunction is a massive one. There are still many unanswered questions.

We don't know optimal research protocols for this specific application. What's the right dosage? What's the most effective administration route? The debate between injectable BPC-157 and oral forms, like our BPC 157 Capsules, is ongoing in the research community, with each having different absorption profiles and potential applications. Injectable forms offer direct systemic availability, while capsules are often studied for their localized effects in the gut, which could still have systemic benefits.

Furthermore, human biology is incredibly complex and variable. A response in one individual may not be replicated in another. The cause of ED can be multifactorial, involving a mix of vascular, neurological, and psychological components. A compound that addresses one aspect may not be enough to solve the entire puzzle for everyone. That's why our mission at Real Peptides is so focused: to provide researchers with impeccably pure and reliable peptides, so they can conduct the studies needed to start answering these critical questions. When you're trying to measure a subtle biological effect, you can't have any doubts about the quality of your tools.

A Holistic View: Where Does BPC-157 Fit In?

So, where does this leave us? The most accurate way to view BPC-157 in the context of erectile dysfunction is not as a standalone 'cure' but as a potential—and powerful—agent for systemic restoration. It’s a tool that may help rebuild the physiological foundation upon which healthy sexual function depends.

True, lasting improvement in health rarely comes from a single source. It comes from a synergistic approach. This means addressing lifestyle factors that are known to contribute to ED: improving diet to reduce inflammation and support vascular health, engaging in regular exercise to boost circulation and nitric oxide production, managing stress, and getting adequate sleep. These are the non-negotiables.

BPC-157, within a research context, could be seen as a catalyst to amplify the body's own healing processes alongside these efforts. It could potentially help repair the damage done by years of a less-than-optimal lifestyle, giving the body a fighting chance to restore its natural function. It’s about shifting the focus from simply overriding a symptom to truly healing the system. That’s the future of this kind of research, and it’s a future we are proud to support by making a comprehensive library of research compounds available. When you're ready to explore these foundational concepts, you can Get Started Today by looking through our full collection.

The conversation around "can BPC 157 help with erectile dysfunction?" is still in its early chapters. But the prologue, written by years of research into its fundamental healing mechanisms, is incredibly promising. It suggests a move away from temporary fixes and toward a future where we can address the root cause of the problem, rebuilding health from the cellular level up. That's a prospect worth investigating.

Frequently Asked Questions

No, it’s fundamentally different. Medications like Viagra are PDE5 inhibitors that work on-demand to temporarily increase blood flow. BPC-157 is a research peptide studied for its potential to systemically repair underlying issues like vascular and nerve damage over time.

The primary proposed mechanism is through angiogenesis, which is the formation of new blood vessels. By potentially improving the density and health of the vascular network, BPC-157 may help restore the body’s natural capacity for blood flow, rather than forcing it temporarily.

Currently, there are no published, large-scale human clinical trials that specifically test BPC-157 for treating ED. The connection is theoretical, based on its well-documented mechanisms of action in tissue repair, angiogenesis, and nerve regeneration from preclinical studies.

Injectable BPC-157 offers direct systemic bioavailability, meaning it enters the bloodstream immediately. Oral forms, like our [BPC 157 Capsules](https://www.realpeptides.co/products/bpc-157-capsules/), are often studied for gut-related issues due to their stability in gastric acid, though they may also have systemic effects.

This is a key area of interest. BPC-157 has shown neuroprotective and neuroregenerative properties in animal studies. Theoretically, its ability to support nerve repair could be beneficial for neurogenic ED, but this requires much more specific research.

BPC-157’s primary research focus is on physical repair and healing. It is not known to directly increase testosterone or act as an aphrodisiac in the way a peptide like [PT-141](https://www.realpeptides.co/products/pt-141-bremelanotide/) does, which works on arousal centers in the brain.

Because it works on a foundational, healing level, any potential effects would be cumulative and not immediate. A research protocol would likely span several weeks or even months to allow time for cellular repair and tissue regeneration to occur.

BPC-157 has shown a high safety profile in preclinical and animal studies with no significant adverse effects reported. However, it’s crucial for researchers to source it from a reputable supplier like Real Peptides to ensure purity and avoid contaminants.

BPC-157’s mechanisms are physiological, focusing on tissue and vascular repair. It is not believed to directly address psychological causes of ED, such as anxiety or depression, though improving physical function could potentially boost confidence.

Yes, some research indicates that BPC-157 can modulate and protect the nitric oxide pathway. Since NO is essential for the vasodilation required for an erection, this is a very compelling and direct potential mechanism of action.

Purity is everything. Contaminants or incorrect peptide sequences can lead to inaccurate research data, unexpected side effects, or a complete lack of efficacy. At Real Peptides, our commitment to small-batch synthesis guarantees the precise, high-purity compounds necessary for reliable scientific inquiry.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

BPC-157 Dosing Structure for Age 50+ Users

The standard BPC-157 50s age specific protocol runs 250–500mcg daily for 4–6 weeks, with higher doses (400–500mcg) reserved for chronic tendinopathy or ligament strain and lower doses (250–350mcg) for acute soft tissue injury. Subcutaneous injection is the most common route. Intramuscular administration offers no documented advantage and increases bruising risk in older populations with reduced capillary integrity. Most researchers split daily doses into two injections (morning and evening) when using 500mcg, though single daily dosing at 250–350mcg is equally effective for localized issues. Injection site proximity matters more than systemic circulation. BPC-157's effects appear to be mediated through local tissue signaling rather than blood concentration. Animal studies show maximum collagen deposition and angiogenesis within 2–3 cm of the injection site. For rotator cuff tendinopathy, inject into the deltoid region near the affected tendon insertion; for patellar tendinitis, inject subcutaneously just above or lateral to the kneecap; for Achilles issues, inject into the calf or directly adjacent to the tendon sheath. Rotating injection points within the target area (rather than using the exact same spot daily) reduces localized irritation and ensures even peptide distribution across the injury zone. Cycle length extends in the BPC-157 50s age specific protocol because tissue remodeling timelines are slower. A 28-year-old with an acute hamstring strain might see functional…
STORAGE

The Storage Breakdown Most Guides Skip

The temperature requirements for BPC-157 aren't arbitrary. They're dictated by the peptide's molecular structure. BPC-157 is a pentadecapeptide (15 amino acids in sequence) derived from body protection compound research. Like all peptides, it exists in one of two states: lyophilised powder or reconstituted solution. Each state has different stability thresholds. Lyophilised BPC-157 can remain stable at −20°C for 12–24 months when stored in a sealed, moisture-free container away from light. This freeze-dried form removes water molecules that would otherwise allow enzymatic degradation and oxidation to occur. The moment you add bacteriostatic water, the stability clock starts. Peptide bonds in aqueous solution are vulnerable to hydrolysis, bacterial contamination (even with bacteriostatic agents), and thermal breakdown. Refrigeration at 2–8°C slows these processes but doesn't stop them entirely. Research-grade Real peptides like BPC-157 rely on precise cold-chain handling from synthesis through end use. Temperature control isn't just best practice. It's what separates an active compound from degraded residue.
02

Question drills

Open a question for its connected answer.

01What If BPC-157 Becomes Available for Off-Label Use Before Clinical Trials Complete?+

This is already happening in some regenerative medicine contexts. Licensed prescribers can legally prescribe BPC-157 off-label if they determine it's medically appropriate for a specific patient. The peptide is available through compounding pharmacies and research peptide suppliers like Real Peptides, which provides research-grade compounds synthesized under strict quality control. However, off-label use without completed clinical trials means patients bear the uncertainty risk. Dosing protocols are based on extrapolation from animal studies, not human pharmacokinetics. We've seen this pattern with other research peptides: early clinical use occurs in parallel with formal trials, and protocols converge as more data emerge. Patients considering off-label use should understand they're participating in de facto observational research.

SOURCE / realpeptides.co ↗
02What If Air Gets Into the Vial During Reconstitution?+

It's unavoidable. Injecting liquid into a sealed vial displaces the air inside, which either compresses or enters the syringe when you draw solution back out. The key is controlling how much air enters. Use a separate needle for reconstitution (18-gauge) and a smaller needle for drawing doses (25–27 gauge). After injecting bacteriostatic water, leave the needle in the stopper and allow pressure to equalise for 10–15 seconds before withdrawing. This prevents backflow that pulls extra air into the vial headspace.

SOURCE / realpeptides.co ↗
03What If Combining BPC-157 and Cartalax with Other Peptides?+

Avoid stacking more than three peptides simultaneously unless each targets a distinct, non-overlapping pathway with evidence supporting additive effects. BPC-157 cartalax protocol joint research already addresses angiogenesis, collagen synthesis, and mitochondrial function. Adding TB-500 (another angiogenic peptide) would create mechanistic redundancy without proportional benefit. If additional pathways need targeting, consider GHK-Cu for copper-dependent collagen cross-linking or Epithalon for telomerase activation in aged cells. But verify through literature review that the combination has precedent in published research rather than anecdotal forums.

SOURCE / realpeptides.co ↗
04What If My Supplier Lists 'Body Protection Compound' Without the 157 Designation?+

Request the amino acid sequence or CAS number immediately. 'body protection compound' without numeric specification could refer to the full-length gastric protein rather than the synthetic 15-amino-acid derivative. The naturally occurring BPC protein is not synthesized commercially, so any supplier claiming to offer it is either mislabeling BPC-157 or providing an entirely different compound. Verify that the product description explicitly states '15-amino-acid sequence' or 'pentadecapeptide,' and confirm the molecular weight is approximately 1419 Da. If the supplier cannot provide HPLC data or sequence confirmation, the peptide should not be used in controlled research.

SOURCE / realpeptides.co ↗
05What if I need guidance on peptide storage after delivery to my Raleigh address?+

Lyophilized peptides remain stable at room temperature for 30-60 days but should be refrigerated at 2-8°C for long-term storage exceeding 90 days. Once reconstituted with bacteriostatic water, BPC-157 must be refrigerated and used within 30 days for optimal potency. Raleigh’s summer humidity does not affect sealed vials, but reconstituted peptides should never be frozen, as ice crystal formation degrades the peptide chain.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

The Documented Truth About BPC-157 Animal Evidence

Here's the honest answer: BPC-157 animal research is extensive, mechanistically detailed, and reproducible across multiple injury models—but it is still preclinical evidence, not human clinical validation. The peptide shows consistent healing acceleration in rodents, with identified mechanisms and dose-response data that meet basic pharmacological research standards. What doesn't exist yet: Phase II or Phase III human trials, FDA-reviewed safety data for long-term use, or regulatory approval for any therapeutic indication. The gap between 'works in rats' and 'approved for human prescription' is substantial, and crossing it requires years of clinical development that hasn't happened for BPC-157. Researchers and institutions studying regenerative peptides continue to build on this animal data because the mechanisms are biologically plausible and the injury models used are validated surrogates for human tissue repair. The Healing Total Recovery Bundle from Real Peptides includes BPC-157 synthesized to research-grade specifications, allowing labs to replicate or extend published animal study protocols. BPC-157 occupies a unique regulatory space: it's available as a research chemical, not as a drug, and its use in humans occurs off-label without formal approval. The animal evidence is compelling enough to sustain ongoing research interest, but not sufficient to claim proven efficacy in humans without acknowledging the translational gap. That gap is real, and it matters. The information in this article is for educational and research purposes—decisions regarding peptide use, dosing, and safety should be made in consultation with qualified professionals and within appropriate regulatory frameworks.

RESEARCH

BPC-157 Studied Shin Splints — Research Evidence Explained

Research published in the Journal of Physiology and Pharmacology demonstrated that BPC-157 accelerated tendon-to-bone healing in rat Achilles models by upregulating growth factors at the damaged periosteal interface. The same tissue layer implicated in medial tibial stress syndrome (shin splints). The peptide increased VEGF expression and collagen type I deposition at injury sites within 7–14 days, suggesting a mechanism relevant to the inflammatory cascade and microtear accumulation that defines shin splint pathology. Human clinical trials remain absent, but the preclinical evidence points to a biological pathway that conventional NSAIDs and rest protocols don't address. Our team has guided researchers and performance athletes through peptide protocol design for musculoskeletal recovery. The gap between what BPC-157 studied shin splints research actually shows and what supplement marketing claims is wider than most realise. What does the research say about BPC-157 studied shin splints recovery? BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a gastric protective protein, studied primarily in animal models for its effects on tendon, ligament, and bone healing. In rodent studies, BPC-157 accelerated healing of Achilles tendon transections and tibial fractures by promoting angiogenesis, collagen synthesis, and fibroblast migration at injury sites. Shin splints. Medial tibial stress syndrome. Involve periosteal inflammation and microtears at the tibial attachment points of the soleus and flexor digitorum longus, making BPC-157's documented effects on tendon-bone interfaces mechanistically relevant. No peer-reviewed human trials on BPC-157 for shin splints exist, but the peptide's mechanism targets the tissue damage pattern that characterises the condition. The research addresses BPC-157 studied shin splints indirectly. Through tendon-bone healing models that replicate the pathology. Most published studies used subcutaneous or intramuscular injections at 10 mcg/kg daily in rats, which translates to approximately 200–500 mcg daily in human dosing equivalents based on body surface area conversion. The peptide isn't FDA-approved for any indication, and compounded versions available through research suppliers operate outside therapeutic approval frameworks. What it does demonstrate is a biological mechanism that conventional shin splint treatments. Rest, ice, stretching. Don't engage.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

BPC-157 Biomarkers: Research vs Clinical Comparison

Inflammatory Cytokines (TNF-α, IL-6, IL-1β) 24–72 hours Serum or tissue ELISA Acute response. Not sustained effect Best for mechanism validation, not endpoint Angiogenesis Markers…

Comparison

Research Peptides for Stress Fracture: BPC-157 vs TB-500 Comparison

Primary Mechanism VEGF/FGF upregulation. Drives angiogenesis and osteoblast recruitment Actin binding. Promotes cell migration, reduces inflammation Dual-pathway: angiogenic + cyt…